Visionox Technology vs CSPC Innovation Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Visionox Technology Inc (002387.CS)

Q3 202614 Jul – 9 Oct 2026

▲3▼1

Visionox loss widens, then Kunshan state capital takes control with 3 billion yuan

First-half loss widens on weak phone panel demand Visionox's first-half 2026 net loss widened to about 1.5 billion yuan as memory-chip price spikes made phone makers order cautiously and flexible OLED phone panel prices fell. Its main business is phone screens, so weaker prices and sales directly cut revenue and margins.
This is the core operating problem weighing on the stock and explains why the company needed rescuing.
Kunshan state capital injects 3 billion yuan and takes control Kunshan Yuanchuang will buy up to 3 billion yuan of new shares, lifting its stake to 30.33% and making Kunshan's zone committee the actual controller. The cash goes to working capital and debt repayment, easing the funding strain from years of losses.
This is the single biggest new event: a state-backed rescue that changes ownership and strengthens the balance sheet.
Push into mid-size OLED and new screen uses Visionox showed laptops, automotive and gaming screens at ChinaJoy, using its ViP technology, and its 8.6-generation line for mid-size panels is in equipment installation. Spreading beyond phones could reduce reliance on the weak, price-war-hit phone screen market.
It shows the company's plan to fix its loss-making phone dependence, a real long-term driver.
Small production-line upgrade contract awarded A supplier won a 47.28 million yuan bid to upgrade Visionox's sixth-generation flexible AMOLED line. It is a modest spending item that supports output capability, but small next to the company's billion-yuan losses.
It is a minor operational positive, included for completeness but far less important than the loss and the state investment.

August 202614 Jul – 9 Oct 2026

▲3▼1

Visionox loss widens, then Kunshan state capital takes control with 3 billion yuan

First-half loss widens on weak phone panel demand Visionox's first-half 2026 net loss widened to about 1.5 billion yuan as memory-chip price spikes made phone makers order cautiously and flexible OLED phone panel prices fell. Its main business is phone screens, so weaker prices and sales directly cut revenue and margins.
This is the core operating problem weighing on the stock and explains why the company needed rescuing.
Kunshan state capital injects 3 billion yuan and takes control Kunshan Yuanchuang will buy up to 3 billion yuan of new shares, lifting its stake to 30.33% and making Kunshan's zone committee the actual controller. The cash goes to working capital and debt repayment, easing the funding strain from years of losses.
This is the single biggest new event: a state-backed rescue that changes ownership and strengthens the balance sheet.
Push into mid-size OLED and new screen uses Visionox showed laptops, automotive and gaming screens at ChinaJoy, using its ViP technology, and its 8.6-generation line for mid-size panels is in equipment installation. Spreading beyond phones could reduce reliance on the weak, price-war-hit phone screen market.
It shows the company's plan to fix its loss-making phone dependence, a real long-term driver.
Small production-line upgrade contract awarded A supplier won a 47.28 million yuan bid to upgrade Visionox's sixth-generation flexible AMOLED line. It is a modest spending item that supports output capability, but small next to the company's billion-yuan losses.
It is a minor operational positive, included for completeness but far less important than the loss and the state investment.

Latest14 Jul – 9 Oct 2026

▲3▼1

Visionox loss widens, then Kunshan state capital takes control with 3 billion yuan

First-half loss widens on weak phone panel demand Visionox's first-half 2026 net loss widened to about 1.5 billion yuan as memory-chip price spikes made phone makers order cautiously and flexible OLED phone panel prices fell. Its main business is phone screens, so weaker prices and sales directly cut revenue and margins.
This is the core operating problem weighing on the stock and explains why the company needed rescuing.
Kunshan state capital injects 3 billion yuan and takes control Kunshan Yuanchuang will buy up to 3 billion yuan of new shares, lifting its stake to 30.33% and making Kunshan's zone committee the actual controller. The cash goes to working capital and debt repayment, easing the funding strain from years of losses.
This is the single biggest new event: a state-backed rescue that changes ownership and strengthens the balance sheet.
Push into mid-size OLED and new screen uses Visionox showed laptops, automotive and gaming screens at ChinaJoy, using its ViP technology, and its 8.6-generation line for mid-size panels is in equipment installation. Spreading beyond phones could reduce reliance on the weak, price-war-hit phone screen market.
It shows the company's plan to fix its loss-making phone dependence, a real long-term driver.
Small production-line upgrade contract awarded A supplier won a 47.28 million yuan bid to upgrade Visionox's sixth-generation flexible AMOLED line. It is a modest spending item that supports output capability, but small next to the company's billion-yuan losses.
It is a minor operational positive, included for completeness but far less important than the loss and the state investment.

CSPC Innovation Pharmaceutical Co Ltd Class A (300765.CS)

Q3 202616 Jul – 14 Sep 2026

▲3

CSPC Innovation Swings to Profit as Cancer Drug Pipeline Hits Key Milestones

Interim profit turnaround confirms commercial ramp CSPC Innovation reported a first-half net profit of 1.261 billion yuan, reversing a year-ago loss, with revenue up 208.7% to 3.24 billion yuan and a 76.7% gross margin. This shows the biopharma business is now generating real cash and earnings, which supports the stock's valuation.
The swing to profit is the clearest fundamental driver of the stock's value and confirms the business is no longer loss-making.
SYS6010 Phase III success and strong lung cancer data SYS6010 met its main goal in a Phase III lung cancer trial, and new data showed it combined with another drug shrank tumors in up to 82.4% of high-PD-L1 patients. These results raise the odds of approval and future sales, boosting investor confidence.
This is the most advanced pipeline asset with late-stage success, directly increasing the probability of a major new revenue stream.
Two new drug applications advance toward market A marketing application for a HER2 ADC for breast cancer was accepted, and a Phase III trial for a B7-H3 ADC in ovarian cancer began. Both move the company closer to adding new approved products, which would broaden future revenue.
These regulatory and clinical steps expand the pipeline and signal more near-term product launches.

August 202616 Jul – 14 Sep 2026

▲3

CSPC Innovation Swings to Profit as Cancer Drug Pipeline Hits Key Milestones

Interim profit turnaround confirms commercial ramp CSPC Innovation reported a first-half net profit of 1.261 billion yuan, reversing a year-ago loss, with revenue up 208.7% to 3.24 billion yuan and a 76.7% gross margin. This shows the biopharma business is now generating real cash and earnings, which supports the stock's valuation.
The swing to profit is the clearest fundamental driver of the stock's value and confirms the business is no longer loss-making.
SYS6010 Phase III success and strong lung cancer data SYS6010 met its main goal in a Phase III lung cancer trial, and new data showed it combined with another drug shrank tumors in up to 82.4% of high-PD-L1 patients. These results raise the odds of approval and future sales, boosting investor confidence.
This is the most advanced pipeline asset with late-stage success, directly increasing the probability of a major new revenue stream.
Two new drug applications advance toward market A marketing application for a HER2 ADC for breast cancer was accepted, and a Phase III trial for a B7-H3 ADC in ovarian cancer began. Both move the company closer to adding new approved products, which would broaden future revenue.
These regulatory and clinical steps expand the pipeline and signal more near-term product launches.

Latest16 Jul – 14 Sep 2026

▲3

CSPC Innovation Swings to Profit as Cancer Drug Pipeline Hits Key Milestones

Interim profit turnaround confirms commercial ramp CSPC Innovation reported a first-half net profit of 1.261 billion yuan, reversing a year-ago loss, with revenue up 208.7% to 3.24 billion yuan and a 76.7% gross margin. This shows the biopharma business is now generating real cash and earnings, which supports the stock's valuation.
The swing to profit is the clearest fundamental driver of the stock's value and confirms the business is no longer loss-making.
SYS6010 Phase III success and strong lung cancer data SYS6010 met its main goal in a Phase III lung cancer trial, and new data showed it combined with another drug shrank tumors in up to 82.4% of high-PD-L1 patients. These results raise the odds of approval and future sales, boosting investor confidence.
This is the most advanced pipeline asset with late-stage success, directly increasing the probability of a major new revenue stream.
Two new drug applications advance toward market A marketing application for a HER2 ADC for breast cancer was accepted, and a Phase III trial for a B7-H3 ADC in ovarian cancer began. Both move the company closer to adding new approved products, which would broaden future revenue.
These regulatory and clinical steps expand the pipeline and signal more near-term product launches.